Trial Profile
A Phase I Study of Dalteparin, a Low Molecular Weight Heparin (LMWH), in Combination With Sunitinib (SU11248), an Oral, Selective Multitargeted Tyrosine Kinase Inhibitor, as First Line Treatment, in Patients With Metastatic Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Aug 2022
Price :
$35
*
At a glance
- Drugs Dalteparin sodium (Primary) ; Sunitinib (Primary)
- Indications Renal cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Apr 2017 Status changed from active, no longer recruiting to completed.
- 13 Jul 2016 This trial was completed in Netherlands (end date: 2015-10-14) according to European Clinical Trials Database record.
- 03 Jun 2014 Interim results (n=19) presented at the 50th Annual Meeting of the American Society of Clinical Oncology.